Predicting circulating human metabolites: how good are we?

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Chemical Research in Toxicology

• Publication date

  2009-01-12

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/tx8004086PMID 19138063
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies.

  2008cited by this paper
• Unique/major human metabolites: why, how, and when to test for safety in animals.

  2008cited by this paper
• Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics

  2008cited by this paper
• Current opinion: safety evaluation of drug metabolites in development of pharmaceuticals.

  2007cited by this paper
• A rapid method for quantitatively estimating metabolites in human plasma in the absence of synthetic standards using a combination of liquid chromatography/mass spectrometry and radiometric detection.

  2007cited by this paper
• A regulatory perspective on issues and approaches in characterizing human metabolites.

  2006cited by this paper
• Detection and Characterization of Metabolites in Biological Matrices Using Mass Defect Filtering of Liquid Chromatography/High Resolution Mass Spectrometry Data

  2006cited by this paper
• Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.

  2006cited by this paper
• Safety assessment of drug metabolites: Characterization of chemically stable metabolites.

  2006cited by this paper
• Metabolites and safety: What are the concerns, and how should we address them?

  2006cited by this paper
• SEEING THROUGH THE MIST: ABUNDANCE VERSUS PERCENTAGE. COMMENTARY ON METABOLITES IN SAFETY TESTING

  2005cited by this paper
• Drug metabolites in safety testing.

  2002cited by this paper

• Investigation of Biotransformation Pathways in a Chimeric Mouse with a Humanized Liver

  2025cites this paper
• Role of metabolites in drug-drug interactions.

  2025cites this paper
• JAK3-deficient mini-pigs exhibit impaired lymphoid organogenesis, intestinal structure, and leukocyte/cytokine production

  2025cites this paper
• Generation of RAG2 Knockout Immune-Deficient Miniature Pigs

  2024cites this paper
• Utility of Common In Vitro Systems for Predicting Circulating Metabolites

  2024cites this paper
• The Current State of Biotransformation Science – Industry Survey of In Vitro and In Vivo Practices, Clinical Translation, and Future Trends

  2024cites this paper
• Empirical scaling factor for predicting human pharmacokinetic profiles of disproportionate metabolites using the Css–MRTpo method and chimeric mice with humanised livers

  2023cites this paper
• Complex Metabolism of the Novel Neurosteroid, Ganaxolone, in Humans: A Unique Challenge for Metabolites in Safety Testing Assessment

  2023cites this paper
• A MIST conception: what has been learned from twenty years of human metabolite safety assessment?

  2023cites this paper
• Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development—Current State-of-the-Art and Future Perspectives

  2022cites this paper
• Structural Modification in Anesthetic Drug Development for Prodrugs and Soft Drugs

  2022cites this paper
• Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data

  2021cites this paper
• Scientific Opinion of the Scientific Panel on Plant Protection Products and their Residues (PPR Panel) on testing and interpretation of comparative in vitro metabolism studies

  2021cites this paper
• CYP2C8-Mediated Formation of a Human Disproportionate Metabolite of the Selective NaV1.7 Inhibitor DS-1971a, a Mixed Cytochrome P450 and Aldehyde Oxidase Substrate

  2021cites this paper
• Evaluation of species differences in the metabolism of the selective NaV1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase

  2021cites this paper
• Art of Making Artificial Liver: Depicting Human Liver Biology and Diseases in Mice

  2020cites this paper
• The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats

  2020cites this paper
• The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats

  2020cites this paper
• Syntheses and pharmacokinetic evaluations of four metabolites of 2-(4-(2-((1H-benzo[d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)-N-(6-methyl-2,4-bis-(methylthio)pyridin-3-yl)acetamide hydrochloride [K-604], an acyl-CoA:cholesterol O-acyltransferase-1 inhibitor.

  2020cites this paper
• Prediction of Human Disproportionate and Biliary Excreted Metabolites Using Chimeric Mice with Humanized Liver

  2020cites this paper
• The Gut-Brain Axis in Neurodegenerative Diseases and Relevance of the Canine Model: A Review

  2019cites this paper
• Comprehensive Evaluation of Organotypic and Microphysiological Liver Models for Prediction of Drug-Induced Liver Injury

  2019cites this paper
• 3D Primary Hepatocyte Culture Systems for Analyses of Liver Diseases, Drug Metabolism, and Toxicity: Emerging Culture Paradigms and Applications

  2019cites this paper
• A common polymorphic variant of UGT1A5 displays increased activity due to optimized cofactor binding

  2018cites this paper
• Advancing Predictive Hepatotoxicity at the Intersection of Experimental, in Silico, and Artificial Intelligence Technologies.

  2018cites this paper
• Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts

  2018cites this paper
• Special Section – New Models in Drug Metabolism and Transport Assessment of the Biotransformation of Low-Turnover Drugs in the H m REL Human Hepatocyte Coculture Model s

  2018cites this paper
• The importance of metabolite pharmacokinetics studies in drug development

  2018cites this paper
• Development of Severe Combined Immunodeficient (SCID) Pig Models for Translational Cancer Modeling: Future Insights on How Humanized SCID Pigs Can Improve Preclinical Cancer Research

  2018cites this paper
• Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor

  2018cites this paper
• Assessment of the Biotransformation of Low-Turnover Drugs in the HµREL Human Hepatocyte Coculture Model

  2018cites this paper
• A decade of drug metabolite safety testing: industry and regulatory shared learning

  2017cites this paper
• Prediction of Losartan-Active Carboxylic Acid Metabolite Exposure Following Losartan Administration Using Static and Physiologically Based Pharmacokinetic Models.

  2017cites this paper
• Simulation of human plasma concentration–time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling

  2017cites this paper
• A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism

  2017cites this paper
• A Comprehensive Overview of the Current Status and Application of Predictive ADMET: Introduction and Overview

  2017cites this paper
• Microdosing, isotopic labeling, radiotracers and metabolomics: relevance in drug discovery, development and safety.

  2017cites this paper
• UNDERSTANDING DRUG METABOLISM IN HUMANS

  2016cites this paper
• A Pharmacokinetic Modeling Approach to Predict the Contribution of Active Metabolites to Human Efficacious Dose

  2016cites this paper
• Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods.

  2016cites this paper
• Assessment of chimeric mice with humanized livers in new drug development: generation of pharmacokinetics, metabolism and toxicity data for selecting the final candidate compound

  2016cites this paper
• Database Extraction of Metabolite Information of Drug Candidates: Analysis of 27 AstraZeneca Compounds with Human Absorption, Distribution, Metabolism, and Excretion Data

  2016cites this paper
• Identification of Three Novel Ring Expansion Metabolites of KAE609, a New Spiroindolone Agent for the Treatment of Malaria, in Rats, Dogs, and Humans

  2016cites this paper
• Can Humanized Mice Predict Drug "Behavior" in Humans?

  2016cites this paper
• Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data

  2016cites this paper
• CELL MODELS FOR STUDYING THE INTERPLAY BETWEEN CONJUGATIVE METABOLISM AND EFFLUX TRANSPORTERS: ESTABLISHING UGT1A1, UGT2B7 AND MRP3 TRANSFECTED MDCK CELL LINES

  2016influential citation
• “MIST” AND OTHER METABOLITE GUIDELINES IN THE CONTEXT OF INDUSTRIAL DRUG METABOLISM

  2016cites this paper
• IN VITRO METHODS FOR EVALUATION OF DRUG METABOLISM

  2016cites this paper
• A comparison between genetically humanized and chimeric liver humanized mouse models for studies in drug metabolism and toxicity.

  2016cites this paper
• Mouse models of human disease evolutionary perspective

  2016cites this paper
• Database extraction of metabolite information of drug candidates: Analysis of 27 AstraZeneca compounds with human ADME data

  2016cites this paper
• Mouse models of human disease

  2016cites this paper
• The role of drug metabolism in drug discovery and development : case ospemifene

  2015cites this paper
• Development of Murine Cyp3a Knockout Chimeric Mice with Humanized Liver

  2015cites this paper
• Analytical challenges for conducting rapid metabolism characterization for QIVIVE.

  2015cites this paper
• DMD066431 1917..1928

  2015cites this paper
• Low-Turnover Drug Molecules: A Current Challenge for Drug Metabolism Scientists

  2015cites this paper
• Chimeric TK-NOG Mice: A Predictive Model for Cholestatic Human Liver Toxicity

  2015cites this paper
• Cardioprotection in ischaemia–reperfusion injury: novel mechanisms and clinical translation

  2015cites this paper
• Early Assessment of Exposure of Drug Metabolites in Humans Using Mass Spectrometry

  2014cites this paper
• In vitro and in vivo metabolism of a novel chymase inhibitor, SUN13834, and the predictability of human metabolism using mice with humanized liver

  2014cites this paper
• Evaluation of human hepatocytes cultured by three-dimensional spheroid systems for drug metabolism.

  2014cites this paper
• Application of Chimeric Mice with Humanized Liver for Study of Human-Specific Drug Metabolism

  2014cites this paper
• Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies

  2014cites this paper
• Pragmatic approaches to determine the exposures of drug metabolites in preclinical and clinical subjects in the MIST evaluation of the clinical development phase.

  2014cites this paper
• Generation of Major Human Excretory and Circulating Drug Metabolites Using a Hepatocyte Relay Method

  2014cites this paper
• Human pharmacogenetic analysis in chimeric mice with ‘humanized livers’

  2013cites this paper
• Chapter 10 – Metabolism and pharmacokinetic optimization strategies in drug discovery

  2013cites this paper
• Metabolite structure analysis by high-resolution MS: supporting drug-development studies.

  2013cites this paper
• Metabolites in Safety Testing

  2013cites this paper
• Can 'humanized' mice improve drug development in the 21st century?

  2013cites this paper
• Using Chimeric Mice with Humanized Livers to Predict Human Drug Metabolism and a Drug-Drug Interaction

  2013influential citation
• Prediction of in vivo metabolite disposition and complex metabolite-dependent drug-drug interactions

  2013influential citation
• Safety Testing of Drug Metabolites: A Practical Approach for the Implementation of the MIST Guidance in PKDM

  2012cites this paper
• The right compound in the right assay at the right time: an integrated discovery DMPK strategy

  2012cites this paper
• Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers

  2012cites this paper
• Predicting Human Biotransformation Pathways

  2012cites this paper
• Clinical Aspects of Drug Biotransformation: An OverviewDedicated to the memory of Mark J. Winn, Ph.D.,1960–1993

  2012cites this paper
• Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?

  2012cites this paper
• The early estimation of circulating drug metabolites in humans

  2012cites this paper
• Prediction of Relative In Vivo Metabolite Exposure from In Vitro Data Using Two Model Drugs: Dextromethorphan and Omeprazole

  2012cites this paper
• Meeting the MIST regulations: human metabolism in Phase I using AMS and a tiered bioanalytical approach.

  2012cites this paper
• Drug Metabolism in Drug Safety Evaluation

  2012cites this paper
• In Vitro Glucuronidation of the Antibacterial Triclocarban and Its Oxidative Metabolites

  2012cites this paper
• Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers

  2012influential citation
• Regiospecific and Stereospecific Triangulation of the Structures of Metabolites Formed by Sequential Metabolism at Multiple Prochiral Centers

  2012cites this paper
• Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?

  2012cites this paper
• Predictability of Metabolism of Ibuprofen and Naproxen Using Chimeric Mice with Human Hepatocytes

  2012cites this paper
• From definition to implementation: a cross-industry perspective of past, current and future MIST strategies

  2011cites this paper
• Assessment of drug metabolites.

  2011cites this paper
• Addressing MIST (Metabolites in Safety Testing): bioanalytical approaches to address metabolite exposures in humans and animals.

  2011cites this paper
• Progression of Drug Metabolism

  2011cites this paper
• Running Title Page Running Title : Glucuronidation of TCC and its metabolites

  2011cites this paper
• １．14Ｃ標識体マイクロドーズ臨床試験の実際と展望 ―プロジェクト・マネージメントの視点から―

  2010cites this paper
• Metabolites in Safety Testing: “MIST” for the Clinical Pharmacologist

  2010cites this paper
• A radiocalibration method with pseudo internal standard to estimate circulating metabolite concentrations.

  2010cites this paper
• Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites.

  2010cites this paper
• Overview of metabolite safety testing from an industry perspective.

  2010cites this paper
• Assessment of a Micropatterned Hepatocyte Coculture System to Generate Major Human Excretory and Circulating Drug Metabolites

  2010cites this paper
• Early human ADME using microdoses and microtracers: bioanalytical considerations.

  2010cites this paper